I suggest that everyone stop focusing on the difference in the results between the USA and Australia and start focusing on the patient selection and/or scoring. Given the numbers in the trials (too large to just be random noise) these results look to be due to a difference in the patients, or in they way they are assessed.
I suspect that the problem is in the way the patients were assessed in the USA.
Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3, page-197
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
-0.020(5.88%) |
Mkt cap ! $579.2M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.0¢ | 32.0¢ | $1.985M | 6.055M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 799885 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 142631 | 7 |
View Market Depth
| Last trade - 16.10pm 08/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |